ANIP vs AZN

ANIP's Piotroski F-Score of 4/9 indicates weak financial health, falling short of the stable threshold and signaling potential operational inefficiencies. The absence of an Altman Z-Score raises concern about bankruptcy risk, especially given a high debt/equity ratio of 1.16. Despite strong revenue growth (29.6% YoY) and solid gross margins (61.36%), the stock trades at a premium to its intrinsic value, with a current price of $70.49 versus a Graham Number of $43.90 and intrinsic value of $23.24. Insider selling activity totaling $3.39M in the last six months further undermines confidence, while technical trends remain bearish. Analysts remain optimistic with a $110.62 target, but this may reflect overvaluation given the underlying financial and sentiment risks.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.